Securian Asset Management Inc. Lowers Holdings in IDEXX Laboratories, Inc. $IDXX

Securian Asset Management Inc. decreased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,308 shares of the company’s stock after selling 120 shares during the quarter. Securian Asset Management Inc.’s holdings in IDEXX Laboratories were worth $2,311,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Mutual of America Capital Management LLC grew its holdings in IDEXX Laboratories by 79.6% in the 1st quarter. Mutual of America Capital Management LLC now owns 19,430 shares of the company’s stock valued at $8,160,000 after buying an additional 8,609 shares during the period. Golden State Wealth Management LLC grew its holdings in IDEXX Laboratories by 3,766.7% in the 1st quarter. Golden State Wealth Management LLC now owns 116 shares of the company’s stock valued at $49,000 after buying an additional 113 shares during the period. Plato Investment Management Ltd grew its holdings in IDEXX Laboratories by 37.1% in the 1st quarter. Plato Investment Management Ltd now owns 3,087 shares of the company’s stock valued at $1,310,000 after buying an additional 835 shares during the period. Genesis Wealth Advisors LLC purchased a new stake in IDEXX Laboratories in the 2nd quarter valued at about $215,000. Finally, ORG Wealth Partners LLC purchased a new stake in IDEXX Laboratories in the 2nd quarter valued at about $273,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Activity

In other IDEXX Laboratories news, Director M Anne Szostak sold 2,187 shares of the company’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total value of $1,415,710.71. Following the transaction, the director directly owned 262 shares of the company’s stock, valued at $169,600.46. This represents a 89.30% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Nimrata Hunt sold 7,143 shares of the company’s stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $630.43, for a total value of $4,503,161.49. Following the completion of the transaction, the executive vice president directly owned 18,007 shares in the company, valued at approximately $11,352,153.01. The trade was a 28.40% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 54,057 shares of company stock worth $34,293,468 in the last ninety days. 0.98% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms have recently weighed in on IDXX. UBS Group began coverage on IDEXX Laboratories in a research note on Wednesday, October 1st. They issued a “neutral” rating and a $720.00 price objective on the stock. Stifel Nicolaus set a $640.00 price objective on IDEXX Laboratories in a research note on Monday, August 4th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of IDEXX Laboratories in a research note on Wednesday, October 8th. Wall Street Zen lowered IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Sunday, September 28th. Finally, BTIG Research lifted their price objective on IDEXX Laboratories from $545.00 to $785.00 and gave the company a “buy” rating in a research note on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $656.50.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $633.78 on Thursday. The stock’s 50 day moving average price is $638.91 and its 200 day moving average price is $554.07. The firm has a market capitalization of $50.70 billion, a PE ratio of 52.77, a price-to-earnings-growth ratio of 4.12 and a beta of 1.58. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, topping the consensus estimate of $3.28 by $0.35. The firm had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.IDEXX Laboratories’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same period in the previous year, the company posted $2.44 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. As a group, sell-side analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.